A systematic review with meta-analysis of fluticasone furoate/vilanterol combination for the treatment of stable COPD
Conclusions FF/VI combination was associated with a decrease of the rate of COPD exacerbations, without affecting mortality or cardiovascular outcomes in patients with moderate to severe stable COPD. Also, the use of FF was associated with an increased risk of pneumonia.
Source: Pulmonary Pharmacology and Therapeutics - Category: Respiratory Medicine Source Type: research
More News: Cardiology | Cardiovascular | Chronic Obstructive Pulmonary | Corticosteroid Therapy | Drugs & Pharmacology | Flonase | Heart | Pneumonia | Respiratory Medicine | Statistics